Spots Global Cancer Trial Database for sonidegib
Every month we try and update this database with for sonidegib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma | NCT03534947 | Basal Cell Carc... Basal Cell Carc... Skin Cancer Invasive Carcin... | Sonidegib Imiquimod Surgery Best supportive... | 18 Years - | Melanoma Institute Australia | |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma | NCT02303041 | Carcinoma, Basa... Recurrent Skin ... Skin Neoplasms Basal Cell Nevu... | Buparlisib Sonidegib | 18 Years - | Stanford University | |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study | NCT05463757 | Basal Cell Carc... Locally Advance... Metastatic Basa... Gorlin Syndrome Basal Cell Nevu... Carcinoma, Basa... Carcinoma Basal Cell Tumo... Skin Cancer Neoplasm of Ski... Neoplasms, Basa... | Vismodegib Sonidegib | - | Maastricht University Medical Center | |
| Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma | NCT04066504 | Basal Cell Carc... | sonidegib | 18 Years - | Sun Pharmaceutical Industries Limited | |
| Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02086552 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Sonidegib | 18 Years - | Mayo Clinic | |
| Tailored Sonidegib Schedule After Complete Response in BCC | NCT04806646 | Locally Advance... | Sonidegib | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | NCT04007744 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me... | Pembrolizumab Sonidegib | 18 Years - | Mayo Clinic | |
| Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma | NCT04066504 | Basal Cell Carc... | sonidegib | 18 Years - | Sun Pharmaceutical Industries Limited | |
| A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | NCT01327053 | Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | NCT02195973 | Recurrent Ovari... | LDE225 | 19 Years - | University of Alabama at Birmingham | |
| Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma | NCT04066504 | Basal Cell Carc... | sonidegib | 18 Years - | Sun Pharmaceutical Industries Limited | |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma | NCT04402073 | Medulloblastoma | Sonidegib Cisplatin Lomustine Vincristine radiotherapy | 15 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tailored Sonidegib Schedule After Complete Response in BCC | NCT04806646 | Locally Advance... | Sonidegib | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | NCT02254551 | Multiple Myelom... | LDE225 Bortezomib | 18 Years - | SCRI Development Innovations, LLC | |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | NCT01431794 | Pancreatic Duct... | LDE225-600mg Gemcitabine nab-paclitaxel LDE225-400mg LDE225-800mg | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | NCT04007744 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me... | Pembrolizumab Sonidegib | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
